|
시장보고서
상품코드
1463082
세계의 뱀 항독소 시장 - 점유율, 규모, 동향, 산업 분석 보고서 : 유형별, 작용기전별, 최종 사용자별, 지역별, 부문별 예측(2024-2032년)Snake Antivenom Market Share, Size, Trends, Industry Analysis Report, By Type (Polyvalent Heterologous, Monovalent Heterologous, Homologous, and Small Molecule Anti-Toxins); By Mode of Action; By End User; By Region; Segment Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계 뱀 항독소 시장 규모는 2032년까지 6억 3,685만 달러에 이를 것으로 예상됩니다. 이 보고서는 현재 시장 역학을 상세하게 통찰하고 미래 시장 성장에 대한 분석을 제공합니다.
다양한 지역에서 일반적인 공중 보건 문제로 뱀 물림 유병률이 증가하고 효과적인 독 중화 솔루션과 치료법에 대한 수요가 증가하고 시장 성장을 견인하고 있습니다. 뱀 물림 식별, 관리 및 치료에 대한 건강 관리 전문가의 의식은 항독소 약물 수요를 촉진합니다. 게다가 보다 효과적인 항독소제제의 개발이나 진단·치료법의 진보를 가져오는 연구개발의 진전이 시장의 성장을 더욱 밀어올릴 것으로 예상됩니다.
예를 들어, 2023년 1월, Ophirex Inc.는 3,700만 달러의 시리즈 B 자금 조달을 완료했다고 발표했습니다. 이 기금은 광범위한 뱀 물기 치료를 전진시키기 위해 임상 개발과 약사 신청을 계속하는 데 사용됩니다.
뱀 물림 부담을 줄이기 위해서는 고유종에 특화된 효과적이고 안전하며 고품질의 제품을 얻는 것이 중요한 요소가 되고 있습니다. 국가 수준에서 특히 생산자의 부족한 지역에서 사용되는 항독소의 경우, 임상 요구를 충족시키기에 충분한 생산량이 없습니다. 따라서, 항독소의 제조 또는 개발 능력을 강화하는 새로운 기회가 탄생하고 있으며, 이는 시장의 성장에도 좋은 재료가 됩니다.
예를 들어 Indian Journal of Medical Research가 2023년 4월에 발표한 보고서에 따르면 인도는 뱀 물기의 예방과 통제를 위한 국가 프로그램에 주력하고 있으며 새로운 효과적인 항독소 개발을 장려한다 합니다.
또한 뱀 항독소 분야의 연구개발 활동에도 중점을 두고 있으며, 이는 주로 새로운 개량형 치료제제의 개발과 전반적인 치료성적 향상 등의 활동을 포함합니다. 이것은 환자가 통증에서 신속하게 회복하는 것을 돕고 세계에서 끊임없이 증가하는 뱀 물기로 인한 사망자 수를 줄입니다.
뱀 항독소 시장 보고서 하이라이트
다가 이종 제형 부문은 최대 점유율을 차지합니다.
신경독 뱀 물기의 유병률 증가와 건강 관리 전문가 간의 채용으로 신경독 부문이 최대 점유율을 차지했습니다.
병원 및 클리닉 부문은 환자 인구의 상당한 증가와 병원 인프라 개선으로 가장 빠른 속도로 성장합니다.
아시아태평양은 뱀 물기의 발생 건수가 증가하고 이로 인해 사망자 수가 증가하고 있기 때문에 세계 시장을 독점할 것으로 예상됩니다.
주요 시장 진출기업은 Boehringer-Ingelheim Thermo Fisher, Hamilton Company, Incepta Vaccine, Novo Nordisk, Rare Disease Therapeutics, Bioclon 등입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 뱀 항독소 시장 인사이트
- 뱀 항독소 시장 - 최종 사용자 스냅샷
- 뱀 항독소 시장 역학
- 성장 촉진요인과 기회
- 뱀 물림 사건 증가와 연구개발 활동에 대한 투자 증가
- 정부의 대처와 자금 제공
- 억제요인과 과제
- 항독소 생산의 고비용
- 성장 촉진요인과 기회
- PESTEL 분석
- 뱀 항독소 시장의 최종 사용자 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 유형별 세계 시장
- 주요 조사 결과
- 소개
- 다가 이종
- 1가 이종
- 상동
- 소분자
제6장 작용기전별 세계 시장
- 주요 조사 결과
- 소개
- 세포독성
- 신경독성
- 혈액독성
- 심장독성
- 근독성
- 기타
제7장 최종 사용자별 세계 시장
- 주요 조사 결과
- 소개
- 병원 및 클리닉
- 외래수술센터(ASC)
- 연구기관
- 기타
제8장 지역별 세계 시장
- 주요 조사 결과
- 소개
- 뱀 항독소 시장 평가, 지역별(2019-2032년)
- 뱀 항독소 시장 - 북미
- 북미 : 뱀 항독소 시장, 유형별(2019-2032년)
- 북미 : 뱀 항독소 시장, 최종사용자별(2019-2032년)
- 북미 : 뱀 항독소 시장, 작용기전별(2019-2032년)
- 뱀 항독소 시장 - 미국
- 뱀 항독소 시장 - 캐나다
- 뱀 항독소 시장 - 유럽
- 유럽 : 뱀 항독소 시장, 유형별(2019-2032년)
- 유럽 : 뱀 항독소 시장, 최종 사용자별 2019-2032년
- 유럽 : 뱀 항독소 시장, 작용기전별(2019-2032년)
- 뱀 항독소 시장 - 영국
- 뱀 항독소 시장 - 프랑스
- 뱀 항독소 시장 - 독일
- 뱀 항독소 시장 - 이탈리아
- 뱀 항독소 시장 - 스페인
- 뱀 항독소 시장 - 네덜란드
- 뱀 항독소 시장 - 러시아
- 뱀 항독소 시장 - 아시아태평양
- 아시아태평양 : 뱀 항독소 시장, 유형별(2019-2032년)
- 아시아태평양 : 뱀 항독소 시장, 최종 사용자별 2019-2032년
- 아시아태평양 : 뱀 항독소 시장, 작용기전별(2019-2032년)
- 뱀 항독소 시장 - 중국
- 뱀 항독소 시장 - 인도
- 뱀 항독소 시장 - 말레이시아
- 뱀 항독소 시장 - 일본
- 뱀 항독소 시장 - 인도네시아
- 뱀 항독소 시장 - 한국
- 뱀 항독소 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 뱀 항독소 시장, 유형별(2019-2032년)
- 중동 및 아프리카 : 뱀 항독소 시장, 최종 사용자별(2019-2032년)
- 중동 및 아프리카 : 뱀 항독소 시장, 작용기전별(2019-2032년)
- 뱀 항독소 시장 - 사우디아라비아
- 뱀 항독소 시장 - UAE
- 뱀 항독소 시장 - 이스라엘
- 뱀 항독소 시장 - 남아프리카
- 뱀 항독소 시장 - 라틴아메리카
- 라틴아메리카 : 뱀 항독소 시장, 유형별(2019-2032년)
- 라틴아메리카 : 뱀 항독소 시장, 최종 사용자별(2019-2032년)
- 라틴아메리카 : 뱀 항독소 시장, 작용기전별(2019-2032년)
- 뱀 항독소 시장 - 멕시코
- 뱀 항독소 시장 - 브라질
- 뱀 항독소 시장 - 아르헨티나
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 파트너십/협업/계약/공개
제10장 기업 프로파일
- Bharat Serums and Vaccine Limited
- Bioclon Institute
- Boehringer-Ingelheim Thermo Fisher
- Boston Scientific Corporation
- BTG International Inc.
- CSL Limited
- Hamilton Company
- Incepta Vaccine Ltd.
- Inosan Biopharma
- Merck & Co. Inc.
- MicroPharm
- Novo Nordisk A/S
- Owen Mumford Ltd.
- Pfizer Inc.
- Rare Disease Therapeutics Inc.
- VINS Bioproducts Limited
The global snake antivenom market size is expected to reach USD 636.85 Million by 2032, according to a new study by Polaris Market Research. The report "Snake Antivenom Market Share, Size, Trends, Industry Analysis Report, By Type (Polyvalent Heterologous, Monovalent Heterologous, Homologous, and Small Molecule Anti-Toxins); By Mode of Action; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising prevalence of snakebites as a common public health issue across various regions and increased demand for effective venom neutralizing solutions or treatments, driving the market's growth. Awareness among healthcare professionals about the identification, management, and treatment of snakebites, fostering the demand for antivenoms. Additionally, growing advances in R&D that results in the creation of more effective antivenom formulations and advancements in diagnostics and treatment methods, are further anticipated to boost market's growth.
For instance, in January 2023, Ophirex Inc., announced that they completed a USD 37 million Series B financing. The funds will be used to continue clinical development and regulatory submission in order to advance broad-spectrum snakebite treatment.
The access to effective, safe, and quality products that are specially tailored to the endemic species has been becoming an important component to reduce the burden of snake bites. At the national level, there is insufficient manufacturing output of antivenoms to meet the clinical needs especially for antivenoms intended for use in region with scarcity of producers. Thus, there is an emerging opportunity for manufacturing or developing antivenoms with enhanced capabilities, which will also bode well for market's growth.
For instance, according to a report published by the Indian Journal of Medical Research in April 2023, India is focusing on a national programme for prevention & control of snakebite in India that encourages the development new and effective antivenoms.
Furthermore, there is a growing emphasis on research & development activities in the field of snake antivenom which mainly includes activities like creation of new improved treatment formulations and improving the overall treatment outcomes. It helps patients quickly recover from the pain and reduces the number of constantly rising deaths due to snakebites across the globe.
Snake Antivenom Market Report Highlights
Polyvalent heterologous segment accounted for the largest share, due to its higher effectiveness and preference over alternative options
Neurotoxic segment held the maximum share, on account of rising prevalence of neurotoxic snakebites and its adoption among healthcare professionals
Hospitals & clinics segment will grow at fastest pace, owing to significant increase in patient population and improvements in hospitals infrastructure
Asia Pacific is expected to dominated the global market, due to rising incidences of snakebites and number of deaths occurs due to thus in the region
The key market players include Boehringer-Ingelheim Thermo Fisher, Hamilton Company, Incepta Vaccine, Novo Nordisk, Rare Disease Therapeutics, and Bioclon
Polaris Market Research has segmented the snake antivenom market report based on type, mode of action, end user, and region:
Snake Antivenom, Type Outlook (Revenue - USD Million, 2019 - 2032)
- Polyvalent Heterologous
- Monovalent Heterologous
- Homologous
- Small Molecule Anti-Toxins
Snake Antivenom, Mode of Action Outlook (Revenue - USD Million, 2019 - 2032)
- Cytotoxic
- Neurotoxic
- Haemotoxic
- Cardiotoxic
- Myotoxic
- Others
Snake Antivenom, End User Outlook (Revenue - USD Million, 2019 - 2032)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Research Institutes
- Others
Snake Antivenom, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Snake Antivenom Market Insights
- 4.1. Snake Antivenom Market - End User Snapshot
- 4.2. Snake Antivenom Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing incidences of snakebites and rising investments on R&D activities spurring the global market growth.
- 4.2.1.2. Government Initiatives and Funding.
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Costs of Antivenom Production.
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Snake Antivenom Market End User Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Snake Antivenom Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 5.3. Polyvalent Heterologous
- 5.3.1. Global Snake Antivenom Market, by Polyvalent Heterologous, by Region, 2019-2032 (USD Million)
- 5.4. Monovalent Heterologous
- 5.4.1. Global Snake Antivenom Market, by Monovalent Heterologous, by Region, 2019-2032 (USD Million)
- 5.5. Homologous
- 5.5.1. Global Snake Antivenom Market, by Homologous, by Region, 2019-2032 (USD Million)
- 5.6. Small Molecule
- 5.6.1. Global Snake Antivenom Market, by Small Molecule, by Region, 2019-2032 (USD Million)
6. Global Snake Antivenom Market, by Mode of Action
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 6.3. Cytotoxic
- 6.3.1. Global Snake Antivenom Market, by Cytotoxic, by Region, 2019-2032 (USD Million)
- 6.4. Neurotoxic
- 6.4.1. Global Snake Antivenom Market, by Neurotoxic, by Region, 2019-2032 (USD Million)
- 6.5. Haemotoxic
- 6.5.1. Global Snake Antivenom Market, by Haemotoxic, by Region, 2019-2032 (USD Million)
- 6.6. Cardiotoxic
- 6.6.1. Global Snake Antivenom Market, by Cardiotoxic, by Region, 2019-2032 (USD Million)
- 6.7. Myotoxic
- 6.7.1. Global Snake Antivenom Market, by Myotoxic, by Region, 2019-2032 (USD Million)
- 6.8. Others
- 6.8.1. Global Snake Antivenom Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Snake Antivenom Market, by End User
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 7.3. Hospitals & Clinics
- 7.3.1. Global Snake Antivenom Market, by Hospitals & Clinics, By Region, 2019-2032 (USD Million)
- 7.4. Ambulatory Surgical Centers
- 7.4.1. Global Snake Antivenom Market, by Ambulatory Surgical Centers, By Region, 2019-2032 (USD Million)
- 7.5. Research Institutes
- 7.5.1. Global Snake Antivenom Market, by Research Institutes, By Region, 2019-2032 (USD Million)
- 7.6. Others
- 7.6.1. Global Snake Antivenom Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Snake Antivenom Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Snake Antivenom Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Snake Antivenom Market - North America
- 8.3.1. North America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.3.2. North America: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.3.3. North America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.3.4. Snake Antivenom Market - U.S.
- 8.3.4.1. U.S.: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.3.5. Snake Antivenom Market - Canada
- 8.3.5.1. Canada: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4. Snake Antivenom Market - Europe
- 8.4.1. Europe: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.2. Europe.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.3. Europe: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.4. Snake Antivenom Market - UK
- 8.4.4.1. UK: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.4.3. UK: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.5. Snake Antivenom Market - France
- 8.4.5.1. France: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.5.2. France.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.5.3. France: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.6. Snake Antivenom Market - Germany
- 8.4.6.1. Germany: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.7. Snake Antivenom Market - Italy
- 8.4.7.1. Italy: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.8. Snake Antivenom Market - Spain
- 8.4.8.1. Spain: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.9. Snake Antivenom Market - Netherlands
- 8.4.9.1. Netherlands: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.4.10. Snake Antivenom Market - Russia
- 8.4.10.1. Russia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5. Snake Antivenom Market - Asia Pacific
- 8.5.1. Asia Pacific: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5.4. Snake Antivenom Market - China
- 8.5.4.1. China: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.4.2. China.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.4.3. China: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5.5. Snake Antivenom Market - India
- 8.5.5.1. India: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.5.2. India.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.5.3. India: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5.6. Snake Antivenom Market - Malaysia
- 8.5.6.1. Malaysia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5.7. Snake Antivenom Market - Japan
- 8.5.7.1. Japan: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5.8. Snake Antivenom Market - Indonesia
- 8.5.8.1. Indonesia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.5.9. Snake Antivenom Market - South Korea
- 8.5.9.1. South Korea: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.6. Snake Antivenom Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.6.4. Snake Antivenom Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.6.5. Snake Antivenom Market - UAE
- 8.6.5.1. UAE: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.6.6. Snake Antivenom Market - Israel
- 8.6.6.1. Israel: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.6.7. Snake Antivenom Market - South Africa
- 8.6.7.1. South Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.7. Snake Antivenom Market - Latin America
- 8.7.1. Latin America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.7.3. Latin America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.7.4. Snake Antivenom Market - Mexico
- 8.7.4.1. Mexico: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.7.5. Snake Antivenom Market - Brazil
- 8.7.5.1. Brazil: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
- 8.7.6. Snake Antivenom Market - Argentina
- 8.7.6.1. Argentina: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Bharat Serums and Vaccine Limited
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Bioclon Institute
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Boehringer-Ingelheim Thermo Fisher
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Boston Scientific Corporation
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. BTG International Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. CSL Limited
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Hamilton Company
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Incepta Vaccine Ltd.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Inosan Biopharma
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Merck & Co. Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. MicroPharm
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Novo Nordisk A/S
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Owen Mumford Ltd.
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Pfizer Inc.
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. Rare Disease Therapeutics Inc.
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development
- 10.16. VINS Bioproducts Limited
- 10.16.1. Company Overview
- 10.16.2. Financial Performance
- 10.16.3. Product Benchmarking
- 10.16.4. Recent Development
